Descripción de la empresa
IO Biotech, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of immune-modulating therapeutic cancer vaccines, utilizing its proprietary T-win technology platform to target both cancer cells and immune-suppressive cells within the tumor microenvironment. The company functions within the broader Healthcare sector, specifically focusing on the Biotechnology industry, a field characterized by high innovation requirements and significant regulatory scrutiny for new drug candidates. At the current time, IO Biotech, Inc. maintains a market capitalization of $3.45M and employs a workforce of 80 individuals to support its research and development initiatives. The relatively modest market capitalization combined with the absence of reported annual revenue figures indicates that the company remains in an early-stage development phase, where value is derived primarily from intellectual property and clinical trial potential rather than commercial sales volume.
Salud financiera
The financial statements for IO Biotech, Inc. reflect a pre-revenue or minimal-revenue stage, with reported Revenue (TTM) listed as N/A, a Net Income (TTM) of $-88,349,000, and an EBITDA of $-91,802,000. The substantial gap between the reported revenue (which is not available) and the significant negative net income reveals a cost structure dominated by heavy research and development expenditures, typical for clinical-stage biotechnology firms attempting to bring novel therapies to market. The company's Free Cash Flow stands at $-49,063,376, indicating a continuous burn rate that consumes liquid assets as the firm invests in its clinical pipeline without current commercial inflows to offset these operational costs. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that suggests the company has not yet achieved commercial scalability or that revenues are insufficient to calculate meaningful margins under current reporting standards. Regarding capital structure, the company holds $30.66M in cash against $18.12M in debt, resulting in a Debt to Equity ratio of 1988.91, which highlights a highly leveraged balance sheet relative to its equity base, although the absolute debt level is partially offset by substantial cash reserves. The Current Ratio is reported at 2.01, suggesting that the company possesses sufficient liquid assets to cover its short-term obligations, providing a degree of liquidity safety despite the overall cash burn. Return on Equity is reported at -240.5% and Return on Assets at -88.6%, metrics that indicate management is currently utilizing the company's capital base to generate negative returns, a common characteristic for biotech firms in the clinical trial phase before product approval and commercialization occur.
Evaluación de valoración
Valuation multiples for IO Biotech, Inc. present unique challenges due to the lack of profitability, with a Trailing P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.13. The negative forward P/E ratio implies that analysts or data providers expect earnings to remain negative or that the forward earnings estimate is so small relative to the negative P/E calculation that it results in a negative figure, reflecting the uncertainty surrounding future profitability for a pre-commercial asset. The Price to Book ratio stands at 3.69, indicating that the market values the company at a premium of 3.69 times its book value, a scenario often seen in biotech firms where the value of intangible assets like patent portfolios and clinical data is not fully captured on the balance sheet. Alternative valuation metrics include a Price to Sales ratio listed as N/A and an EV/EBITDA of 0.13; the low EV/EBITDA figure reflects the company's high enterprise value relative to its small, negative earnings, suggesting the market is pricing in significant future growth potential rather than current earnings power. The stock's recent trading range shows a 52-Week High of $2.79 and a 52-Week Low of $0.03, meaning the current price sits significantly closer to the bottom of the range, having experienced a substantial decline from its recent peak. The Beta value is recorded at 0.89, which indicates that the stock's price volatility is slightly lower than the broader market, suggesting that IO Biotech, Inc. has exhibited less price fluctuation than the overall market index over the measured period.
Growth & Income
IO Biotech, Inc. reports Revenue Growth (YoY) as N/A and Earnings Growth (YoY) as N/A, reflecting the company's status as a pre-revenue entity where historical growth rates cannot be calculated due to the absence of substantial prior-year revenue or earnings data. Since the company is not a dividend payer, the Dividend Yield is listed as N/A and the Payout Ratio is 0.0%, which signifies that the firm reinvests all available resources, including its cash reserves, directly into research, development, and clinical trials to advance its T-win technology platform. The absence of a dividend yield combined with significant negative earnings growth rates (indicated by the lack of positive earnings) implies that the company prioritizes capital allocation toward achieving clinical milestones and regulatory approval rather than distributing income to shareholders. The overall growth and income profile for IO Biotech, Inc. is defined by a complete reliance on external capital or cash reserves to fund operations, with no current income generation to support shareholder returns or organic revenue growth.